An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for expanded access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how policymakers view specialty peptide therapies, which have drawn steady interest from consumers seeking alternatives to conventional drugs. Researchers say peptide treatments could reshape approaches to resistant infections, though concerns about quality persist. The committee's endorsement of six peptides opens the door for more widespread prescribing, even as critics warn of limited evidence. Market watchers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on some peptide candidates.